ReWalk Robotics Reports First Quarter

ReWalk Robotics Reports First Quarter

2019 Financial Results

- 2019 first quarter

total revenue of $1.6 million -

ReStore Exo-Suit launch timeline -

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, May 7, 2019 -

ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced its financial

results for the three months ended March 31, 2019.

of and subsequent to the first quarter of 2019 include:

believe that 2019 will become a turning point for ReWalk due to SCI reimbursement expansion and our entry into the stroke rehab

market place. Europe continues to demonstrate positive signs of increased acceptance for our SCI Personal 6.0 device, and the

recent U.S. activities show the same trend. All activities for the ReStore exo-suit including regulatory clearance, successful

production and launch in the Unites States and Europe are on track with our plan. We have strengthened our balance sheet with

the April round and the Company remains committed to reducing its operating expenses by more than 10% in 2019." stated Larry

Jasinski, Chief Executive Officer of ReWalk.

Quarter 2019 Financial Results

Total revenue was $1.6 million for

the first quarter of 2019, compared to $1.6 million during the prior year quarter. 14 ReWalk systems were placed during the first

quarter of 2019, compared to 23 systems in the prior year period. Ten units were placed in Europe, three in the U.S and one

was placed in other markets.

Gross margin was 59% during the first

quarter of 2019, compared to 43% in the first quarter of 2018, the increase is primarily attributable to higher average selling

price due to change in sales mix of our ReWalk Personal device.

Total operating expenses in the first

quarter of 2019 were $4.5 million, compared to $6.5 million in the prior year period.

Net loss was $4.0 million for the

first quarter of 2019, compared to a net loss of $6.3 million in the first quarter of 2019.

Non-GAAP net loss for the first quarter

of 2019 was $3.6 million, compared with a non-GAAP net loss of $5.4 million in the first quarter of 2018. A reconciliation of

net loss to non-GAAP net loss is included at the end of this press release.

As of March 31, 2019, ReWalk had $8.9

million in cash on its balance sheet and $8.3 million in short- and long-term debt. Our March 31, 2019 cash balance on a pro-forma

basis including the registered direct offering closed on April 5, 2019 was $12.6 million.

ReWalk management will host its first

quarter 2019 conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 7553177.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

ReWalk's mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation

and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.

For more information on the ReWalk systems, please visit www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel and the United States.

ReStore is a registered trademark

of ReWalk Robotics Ltd in Europe.

Forward-Looking Statements

In addition to historical information, this press release contains

forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the

U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may

include projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate,"

"assume," "believe," "continue," "could," "estimate," "expect,"

"intend," "may," "plan," "potential," "predict," "project,"

"future," "will," "should," "would," "seek" and similar terms or phrases.

The forward-looking statements contained in this press release are based on management's current expectations, which are

subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's

control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking

statements include, among others: ReWalk's ability to secure capital from its equity and debt financings in light of limitations

under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings

may dilute ReWalk's shareholders or restrict its business; ReWalk's ability to maintain compliance with the continued

listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; the

risk of decreased liquidity in the market for ReWalk's ordinary shares and a reduced market capitalization of the Company

following the recently-effected reverse share split, and the risk of dilution following the recently-effected increase in authorized

share capital; ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic

markets, and to expand to new markets and achieve its planned expense reductions; the conclusion of ReWalk's management

and the opinion of ReWalk's auditors in that there are substantial doubts as to ReWalk's ability to continue as a

going concern; ReWalk's ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's

ability to achieve reimbursement from third-party payors for its products; ReWalk's limited operating history and its ability

to leverage its sales, marketing and training infrastructure; ReWalk's expectations as to its clinical research program

and clinical results; ReWalk's ability to improve its products and develop new products; ReWalk's ability to repay

its secured indebtedness; the outcome of ongoing shareholder class action litigation relating to ReWalk's initial public

offering; ReWalk's compliance with medical device reporting regulations to report adverse events involving its products

and the potential impact of such adverse events on ReWalk's ability to market and sell its products; ReWalk's ability

to gain and maintain regulatory approvals; ReWalk's expectations as to the results of, and the Food and Drug Administration's

potential regulatory developments with respect to, ReWalk's mandatory post-market 522 surveillance study and ReWalk's

510k submission for the ReStore for stroke patients; ReWalk's ability to maintain adequate protection of its intellectual

property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of

our IT systems significantly disrupting our business operations; ReWalk's ability to use effectively the proceeds of offerings

of securities; ReWalk's ability to establish a pathway to commercialize its products in China; the risk of substantial dilution

resulting from the periodic issuances of ReWalk's ordinary shares; ReWalk's ability to maintain relationships with

existing customers and develop relationships with new customers; the impact of the market price of ReWalk's ordinary shares

on the determination of whether ReWalk is a passive foreign investment company; and other factors discussed under the heading

"Risk Factors" in ReWalk's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with

the U.S. Securities and Exchange Commission (the "SEC") and other documents subsequently filed with or furnished to

the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could

cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not

possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any

forward-looking statements, whether as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which

are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use

of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three months ended March 31, 2019 and 2018, non-GAAP

net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation and (iii) non-cash

Because of varying available valuation

methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash expenses,